Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 9, 2011, Pages 1999-2006

  Buchanan, Ian M ^a,b,c   Scott, Tamalee ^a   Tandle, Anita T ^a   Burgan, William E ^d   Burgess, Teresa L ^e   Tofilon, Philip J ^f   Camphausen, Kevin ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c BROWN UNIVERSITY   (United States)

^d SAIC FREDERICK INC   (United States)

^e AMGEN INC   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

AMG102; Glioblastoma; HGF; Met; Radiation

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RILOTUMUMAB; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ANIMAL; ARTICLE; CELL DEATH; CELL PROLIFERATION; DNA DAMAGE; DRUG EFFECT; GLIOMA; HUMAN; IMMUNOLOGY; IONIZING RADIATION; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DNA DAMAGE; GLIOMA; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-MET; RADIATION TOLERANCE; RADIATION, IONIZING; SIGNAL TRANSDUCTION;

MUS;

EID: 77958603109     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01122.x     Document Type: Article

References (49)

1. Pazdur R, Wagman LD, Camphausen KA, et al. Cancer management: a multidiciplinary approach, medical, surgical, & radiation oncology. In: Oncology, editor. 11 ed. Lawrence, KS, USA: CMP Medica, 2008.
2. Cooper C, Park M, Blair D, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984; 311: 29-33.
3. Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987; 327: 239-42.
4. Nakamura T, Nishikawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature. 1989; 342: 440-3.
5. Weidner KM, Arakaki N, Hartmann G, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA. 1991; 88: 7001-5.
6. Bottaro D, Rubin J, Faletto D, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991; 251: 802-4.
7. Higuchi O, Nakamura T. Identification and change in the receptor for hepatocyte growth factor in rat liver after partial hepatectomy or induced hepatitis. Biochem Biophys Res Commun. 1991; 176: 599-607.
8. Watanabe S, Hirose M, Wang XE, et al. Hepatocyte growth factor accelerates the wound repair of cultured gastric mucosal cells. Biochem Biophys Res Commun. 1994; 199: 1453-60.
9. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003; 4: 915-25.
10. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Let. 2005; 225: 1-26.
11. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008; 7: 504-16.
12. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer. 2006; 6: 637-45.
13. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997; 57: 5391-8.
14. Rosen EM, Laterra J, Ansamma J, et al. Scatter factor expression and regulation in human glial tumors. Int J Cancer. 1996; 67: 248-55.
15. Athauda G, Giubellino A, Coleman JA, et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res. 2006; 12: 4154-62.
16. Lal B, Xia S, Abounader R, et al. Targeting the c-Met pathway potentiates glioblastoma responses to {gamma}-radiation. Clin Cancer Res. 2005; 11: 4479-86.
17. Sheng-hua C, Zhi-an Z, Xian-hou Y, et al. In vitroandin vivopotentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides. J Neurooncol. 2006; 80: 143-9.
18. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res. 2006; 66: 1721-9.
19. Burgess TL, Sun J, Meyer S, et al. Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor. Mol Cancer Ther. 2010; 9: 400-9.
20. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 2007; 13: 6735-42.
21. Gao CF, Xie Q, Zhang YW, et al. Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. Mol Cancer Ther. 2009; 8: 2803-10.
22. Davis IJ, McFadden AW, Zhang Y, et al. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res. 2010; 70: 639-45.
23. Xu B, Kim S-T, Lim D-S, et al. Two molecularly distinct G2/M checkpoints are induced by ionizing irradiation. Mol Cell Biol. 2002; 22: 1049-59.
24. Qian L-W, Mizumoto K, Inadome N, et al. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulationviaupregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer. 2003; 104: 542-9.
25. Schweigerer L, Rave-Fränk M, Schmidberger H, et al. Sublethal irradiation promotes invasiveness of neuroblastoma cells. Biochem Biophys Res Commun. 2005; 330: 982-8.
26. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. In J Radiat OncolBiolPhys. 2004; 59: 928-42.
27. Cilby W, Roberts C, Cimprich K, et al. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. EMBO J. 1998; 17: 159-69.
28. Wang Y, Li J, Booher RN, et al. Radiosensitization of p53 Mutant Cells by PD0166285, a Novel G2 Checkpoint Abrogator. Cancer Res. 2001; 61: 8211-7.
29. Broker LE, Kruyt FAE, Giaccone G. Cell death independent of caspases: a review. Clin Cancer Res. 2005; 11: 3155-62.
30. Olive PL. The role of DNA single- and double-strand breaks in cell killing by ionizing radiation. Radiat Res. 1998; 150: S42-52.
31. Banath JP, Olive PL. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res. 2003; 63: 4347-50.
32. Bonner WM, Redon CE, Dickey JS, et al. [gamma]H2AX and cancer. Nat Rev Cancer. 2008; 8: 957-67.
33. Rogakou EP, Pilch DR, Orr AH, et al. DNA Double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998; 273: 5858-68.
34. Olive PL, Banath JP. The comet assay: a method to measure DNA damage in individual cells. Nat Protocols. 2006; 1: 23-9.
35. CBTRUS. Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2005. Hinsdale, IL: Central Brain Tumor Registry of the United States; 2009.
36. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-96.
37. Gordon MS, Sweeney CS, Mendelson DS, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res. 2010; 16: 699-710.
38. Gao C-F, Xie Q, Su Y-L, et al. Proliferation and invasion: plasticity in tumor cells. Proc Nat Acad Sci USA. 2005; 102: 10528-33.
39. Toulany M, Dittmann K, Fehrenbacher B, et al. PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cellsin vitro. DNA Repair. 2008; 7: 1746-56.
40. Kim M-J, Byun J-Y, Yun C-H, et al. c-Src-p38 mitogen-activated protein kinase signaling is required for Akt activation in response to ionizing radiation. Mol Cancer Res. 2008; 6: 1872-80.
41. Fan S, Gao M, Meng Q, et al. Role of NF-[kappa]B signaling in hepatocyte growth factor//scatter factor-mediated cell protection. Oncogene. 2005; 24: 1749-66.
42. Miller AC, Luo L, Chin WK, et al. Proto-oncogene expression: a predictive assay for radiation biodosimetry applications. Radiat Prot Dosimetry. 2002; 99: 295-302.
43. Fan S, Ma Y, Wang J, et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene. 2000; 19: 2212-23.
44. Ganapathipillai SS, Medova M, Aebersold DM, et al. Coupling of mutated Met variants to DNA repairviaAbl and Rad51. Cancer Res. 2008; 68: 5769-77.
45. Welsh J, Mahadevan D, Ellsworth R, et al. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol. 2009; 4: 69.
46. Kim KJ, Wang L, Su Y-C, et al. Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin Cancer Res. 2006; 12: 1292-8.
47. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007; 67: 4408-17.
48. Eder JP, Vande Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009; 15: 2207-14.
49. Scott AM, Lee F-T, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci. 2007; 104: 4071-6.